Candriam S.C.A. Decreases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Candriam S.C.A. decreased its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 18.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 365,999 shares of the company's stock after selling 84,993 shares during the period. Candriam S.C.A. owned 0.58% of Vera Therapeutics worth $15,478,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Holocene Advisors LP lifted its position in Vera Therapeutics by 8.8% during the third quarter. Holocene Advisors LP now owns 1,954,528 shares of the company's stock valued at $86,390,000 after acquiring an additional 158,451 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Vera Therapeutics by 2.1% during the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company's stock worth $44,415,000 after buying an additional 20,223 shares during the period. Jennison Associates LLC grew its holdings in shares of Vera Therapeutics by 82.0% during the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company's stock valued at $34,418,000 after buying an additional 366,763 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Vera Therapeutics by 19.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 430,665 shares of the company's stock valued at $18,213,000 after acquiring an additional 68,860 shares during the period. Finally, Lord Abbett & CO. LLC increased its position in shares of Vera Therapeutics by 41.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock valued at $18,830,000 after acquiring an additional 124,197 shares during the period. Hedge funds and other institutional investors own 99.21% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have commented on VERA. Wolfe Research initiated coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target for the company. Wedbush lifted their target price on Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a report on Friday, November 8th. The Goldman Sachs Group started coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 target price on the stock. Guggenheim raised their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Finally, Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a report on Thursday, November 21st. They issued an "overweight" rating and a $70.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Vera Therapeutics has a consensus rating of "Buy" and an average price target of $64.67.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $46.94, for a total value of $821,450.00. Following the completion of the transaction, the chief executive officer now owns 85,942 shares of the company's stock, valued at $4,034,117.48. This trade represents a 16.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold 52,500 shares of company stock valued at $2,305,625 in the last 90 days. Company insiders own 21.70% of the company's stock.

Vera Therapeutics Trading Down 1.6 %

Vera Therapeutics stock traded down $0.48 during trading on Friday, hitting $28.82. The company had a trading volume of 608,437 shares, compared to its average volume of 893,485. Vera Therapeutics, Inc. has a 1-year low of $25.99 and a 1-year high of $51.61. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The company's 50 day simple moving average is $34.70 and its 200-day simple moving average is $40.07. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -11.04 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.11. As a group, analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.